Cancer Genome and what it means ;-)

by Jon Preston 5 Replies latest watchtower bible

  • Jon Preston
    Jon Preston

    This is from science daily.....

    Genome of Longest-Living Cancer: 11,000-Year-Old Living Dog Cancer Reveals Its Origin, Evolution

    Jan. 23, 2014 — A cancer normally lives and dies with a person, however this is not the case with a sexually transmitted cancer in dogs. In a study published in Science, researchers have described the genome and evolution of this cancer that has continued living within the dog population for the past 11,000 years.

    Scientists have sequenced the genome of the world's oldest continuously surviving cancer, a transmissible genital cancer that affects dogs. This cancer, which causes grotesque genital tumors in dogs around the world, first arose in a single dog that lived about 11,000 years ago. The cancer survived after the death of this dog by the transfer of its cancer cells to other dogs during mating.

    The genome of this 11,000-year-old cancer carries about two million mutations -- many more mutations than are found in most human cancers, the majority of which have between 1,000 and 5,000 mutations. The team used one type of mutation, known to accumulate steadily over time as a "molecular clock," to estimate that the cancer first arose 11,000 years ago.

    "The genome of this remarkable long-lived cancer has demonstrated that, given the right conditions, cancers can continue to survive for more than 10,000 years despite the accumulation of millions of mutations," says Dr Elizabeth Murchison, first author from the Wellcome Trust Sanger Institute and the University of Cambridge.

    The genome of the transmissible dog cancer still harbors the genetic variants of the individual dog that first gave rise to the cancer 11,000 years ago. Analysis of these genetic variants revealed that this dog may have resembled an Alaskan Malamute or Husky. It probably had a short, straight coat that was colored either grey/brown or black. Its genetic sequence could not determine if this dog was a male or a female, but did indicate that it was a relatively inbred individual.

    "We do not know why this particular individual gave rise to a transmissible cancer," says Dr Murchison, "But it is fascinating to look back in time and reconstruct the identity of this ancient dog whose genome is still alive today in the cells of the cancer that it spawned."

    Transmissible dog cancer is a common disease found in dogs around the world today. The genome sequence has helped scientists to further understand how this disease has spread.

    "The patterns of genetic variants in tumors from different continents suggested that the cancer existed in one isolated population of dogs for most of its history," says Dr Murchison. "It spread around the world within the last 500 years, possibly carried by dogs accompanying seafarers on their global explorations during the dawn of the age of exploration."

    Transmissible cancers are extremely rare in nature. Cancers, in humans and animals, arise when a single cell in the body acquires mutations that cause it to produce more copies of itself. Cancer cells often spread to different parts of the body in a process known as metastasis. However, it is very rare for cancer cells to leave the bodies of their original hosts and to spread to other individuals. Apart from the dog transmissible cancer, the only other known naturally occurring transmissible cancer is an aggressive transmissible facial cancer in Tasmanian devils that is spread by biting.

    "The genome of the transmissible dog cancer will help us to understand the processes that allow cancers to become transmissible," says Professor Sir Mike Stratton, senior author and Director of the Sanger Institute. "Although transmissible cancers are very rare, we should be prepared in case such a disease emerged in humans or other animals. Furthermore, studying the evolution of this ancient cancer can help us to understand factors driving cancer evolution more generally."

    Just sayin....

    Cleric: Jon Preston

  • snare&racket
    snare&racket

    Amazing thanks,

    Cancers have the means to nourish themselves by releasing angiogenesis hormones, promoting new blood vessels to develop between the host and the cancer. This is the case in all cancers that grow.

    I imagine this is an important process in a transferable cancer between dogs. Developing a source for nutrition and cellular respiration as quickly as possible is essential to this canine cancer I am sure. It must have refined those neovascular mechanisms somewhat.

    I would be focusing on that mechanism and looking for chinks in the chain or something that labels these processes as unique so we can screen for them for early diagnosis or localising neoplasia, if they are also found in humans.

    Great post Jon x

  • RottenRiley
    RottenRiley

    How about the injection of the Chicken Pox virus to fight off child-hood cancers? NIH, interestingly one of my friends has decided to help Marina bring their RNAi tech to fruition because they need good strong leadership, he will bring that talent and help find capital to build up their technology, RNAi and sRNAi are the future, Amylin had a great product portfolio but got gobbled up. I like people and doctors who want to make this World a better place instead of putting your head in the sand until somebody yells "It Peace and Security, Run to the inner chambers and find the Dukes of Hazzardous Religion!"

    "

    Marina Biotech Achieves Broad Patent Coverage for DiLA2 Nucleic Acid Delivery Technology in U.S., Europe and Japan

    Company Receives Patent Notice From Japan Patent Office

    BOSTON, MA--(Marketwired - Jan 23, 2014) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading oligonucleotide-based drug discovery and development company, announced today that a decision to grant a patent has been issued for the Company's Di-alkylated Amino Acid (DiLA2) liposomal delivery technology in Japan (Ser No 2010-506690). The claims of this National Stage Application broadly cover DiLA2 compounds, as well as compositions containing therapeutic nucleic acids, and uses for treating a wide range of diseases. The patent claims granted in Japan cover norarginine- and pyridylalanine-based compounds, which are known to be some of the most efficacious liposome-forming compounds developed by Marina Biotech for delivery of nucleic acid-based therapeutics. In addition, the European Patent Office has agreed to the allowance of broad DiLA2 patent claims, which will be granted. A DiLA2 patent has previously been issued in the U.S. and China. Thus, with the decision to grant from the Japan Patent Office, Marina Biotech has achieved broad coverage for the DiLA2 patent estate in the four largest commercial markets.

    "Our proprietary DiLA2 delivery technology provides a means for creating an extensive library of delivery formulations that may be tailored for delivery of nucleic acid-based therapeutics to specific tissues," stated J. Michael French, President and CEO at Marina Biotech. "The versatility of the DiLA2 platform provides for a rapid and scientifically robust process for improving the delivery characteristics of novel formulations to meet specific requirements for a particular therapeutic application, i.e., administration via systemic or local delivery. We have demonstrated physical and chemical stability for over a year in storage conditions of -40°C while maintaining in vivo activity as well as effective systemic delivery of a microRNA in a subcutaneous tumor cancer model. Further, our preclinical effort in bladder cancer utilizes the DiLA2 delivery technology. The broad patent coverage for both our DiLA2 and SMARTICLES® delivery technologies establishes our competitive advantage in delivering nucleic acid-based therapeutics."

    About Marina Biotech, Inc.Marina Biotech is an oligonucleotide therapeutics company with the broadest drug discovery platform in the sector providing the ability to develop proprietary single and double-stranded nucleic acid therapeutics including siRNAs, microRNA mimics, antagomirs, and antisense compounds, including messengerRNA therapeutics. The platform was built via a roll-up strategy to discover and develop any number of different types of nucleic acid therapeutics in order to modulate (up or down) a specific protein(s) which is either being produced too much or too little causing a particular disease. We believe that Marina Biotech is the only company in the sector with this breadth of capability, and as a result the platform has unique strengths as a drug discovery engine for the development of nucleic acid-based therapeutics for rare and orphan diseases. Further, we believe Marina is the only company in the sector that has a delivery technology in human clinical trials with differentiated classes of payloads, through licensees ProNAi Therapeutics and Mirna Therapeutics, delivering single-stranded and double-stranded nucleic acid payloads, respectively. Our novel chemistries and other delivery technologies have been validated through license agreements with Roche, Novartis, Monsanto, and Tekmira. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs -- in bladder cancer and myotonic dystrophy. Marina Biotech's goal is to improve human health through the development of RNAi- and oligonucleotide-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available atwww.marinabio.com.

    Forward-Looking StatementsStatements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Marina Biotech to obtain additional funding; (ii) the ability of Marina Biotech to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) the ability of Marina Biotech and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) the ability of Marina Biotech and/or a partner to obtain required governmental approvals; and (v) the ability of Marina Biotech and/or a partner to develop and commercialize products prior to, and that can compete favorably with those of, competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Marina Biotech's most recent filings with the Securities and Exchange Commission. Marina Biotech assumes no obligation to update and supplement forward-looking statements because of subsequent events.

    CONTACT INFORMATION

    • Marina Biotech, Inc.
      J. Michael French
      President and Chief Executive Officer
      (425) 892-4322
      [email protected]

  • snare&racket
    snare&racket

    Why did you post that? It is just a patent for a biological delivery mechanism of treatments.

    back to the cancer chat....

  • Jon Preston
    Jon Preston

    Lol snare. Thanks for the info rotten....

    hm why did Jehovah create cancer

  • sir82
    sir82

    11,000 years ago....so "evidently" this cancer was one of the "good" creations of Jehovah, since he said after creative days 1 thru 6, "it was good".

    What a loving provision from Jehovah!

Share this

Google+
Pinterest
Reddit